x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

RhAPPcast

Rheumatology Advanced Practice Providers (RhAPP)

This is the official podcast of Rheumatology Advanced Practice Providers (RhAPP), a non-profit 501c3 organization dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). Through our peer-to-peer network, we seek to support the integral role APPs play in the rheumatology healthcare community by providing the most relevant and timely information and communication for the treatment of

health & fitness medicine

All Episodes

25:33

RhAPPcast: Expanding the Arsenal: JAK Inhibitors in...

RhAPPcast ·

2025/09/18

Welcome to RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers. In this fourth episode of our GCA Fireside Chat series, host Amanda Mixon is joined by nurse practitioner Naomi Amudala and clinical pharmacist Jessica Farrell to explore the evolving role of JAK inhibitors in the treatment of giant cell arteritis (GCA). Building on insights from the SELECT-GCA study, the discussion dives into how JAK inhibition may fit into clinical practice—covering patient selection, safety

en

01:39

Medication Review: How is Sarilumab Dosed &...

RhAPPcast ·

2025/09/16

In this educational video, Heather Mambretti, PA-C with over 13 years of rheumatology experience, explains how sarilumab is dosed and what patients can expect during administration for both rheumatoid arthritis (RA) and polymyalgia rheumatica (PMR). She discusses the convenience of the subcutaneous auto-injector, which allows patients to self-administer at home, and reviews the standard dosing regimen of 200 mg every two weeks with no loading dose required. Heather also addresses how to adjust to a

en

02:43

Medication Review: Key Patient Education When...

RhAPPcast ·

2025/09/09

Starting a new biologic can be overwhelming for patients with polymyalgia rheumatica (PMR) or rheumatoid arthritis (RA). In this medication review, Heather Mambretti, PA-C, shares the key educational points she discusses when initiating sarilumab. She explains treatment goals—including reducing symptoms, improving quality of life, and, in RA, aiming for remission—while also highlighting why sarilumab is the first and only biologic approved for PMR (FDA approval in 2023) and its established role in

en

28:24

RhAPPcast: Inside the Evidence: A Deep Dive into the...

RhAPPcast ·

2025/09/04

In this episode of RhAPPcast, the official podcast of rheumatology advanced practice providers, host Amanda Mixon continues the GCA Fireside Chat series with a deep dive into the SELECT-GCA trial—one of the most significant recent studies in giant cell arteritis (GCA). Joined by Naomi Amadala, CRNP, and Dr. Peter Merkel, professor of medicine and epidemiology at the University of Pennsylvania and lead author of the New England Journal of Medicine paper, this discussion unpacks the study’s design,

en

39:44

RhAPPcast: Laying the Foundation: Historical...

RhAPPcast ·

2025/09/02

Welcome back to RhAPPcast, the official podcast of rheumatology advanced practice providers. In this episode, host Amanda Mixon continues the GCA Fireside Chat series, focusing on the evolving treatment landscape for giant cell arteritis (GCA). Together with expert guests Naomi Amudala, CRNP, and Dr. Michael Putman, we explore the real-world challenges and clinical decision-making that go beyond diagnosis. Focusing on the therapeutic landscape prior to upadacitinib approval, this episode ranges from

en

01:47

FAQ: What is the Role of Sarilumab in Managing PMR?

RhAPPcast ·

2025/09/02

In this video, Claudia Rivera Salas, NP, a rheumatology nurse practitioner in East Lansing, Michigan, discusses the role of sarilumab in the management of polymyalgia rheumatica (PMR). Sarilumab is a fully human IL-6 receptor blocker administered as a 200 mg subcutaneous injection every two weeks. By targeting IL-6, a key pro-inflammatory cytokine driving muscle pain, stiffness, and systemic inflammation in PMR, sarilumab helps reduce disease activity, prevent flares, and enable more successful

en

06:33

Journal Club: Comparative Effectiveness of Sarilumab...

RhAPPcast ·

2025/08/26

In this Journal Club discussion, Jeannette Hart, PA-C, reviews the landmark SAPHYR trial evaluating sarilumab for patients with polymyalgia rheumatica (PMR) who relapse during glucocorticoid tapering. PMR affects thousands of patients worldwide, with nearly half experiencing relapse when reducing prednisone or other glucocorticoids. For decades, treatment options were limited to steroids despite their well-known side effects and long-term risks. This episode highlights how IL-6 receptor blockade

en

41:37

RhAPPcast: Where We Stand: Current Approaches to...

RhAPPcast ·

2025/08/21

Welcome back to RhAPPcast, the official podcast of rheumatology advanced practice providers. In this episode, host Amanda Mixon continues the GCA Fireside Chat series, focusing on the evolving treatment landscape for giant cell arteritis (GCA). Together with expert guests Naomi Amadala, CRNP, and Dr. Michael Putnam, we explore the real-world challenges and clinical decision-making that go beyond diagnosis. From high-dose steroids to steroid-sparing agents such as IL-6 inhibitors and methotrexate,

en

03:58

FAQ Video Module: Choosing Between Steroid-Sparing...

RhAPPcast ·

2025/08/19

In this FAQ Video Module, Claudia Rivera Salas, NP, a rheumatology nurse practitioner in East Lansing, Michigan, explains how clinicians choose between steroid-sparing agents for the treatment of polymyalgia rheumatica (PMR). She outlines when methotrexate may be used as a cost-effective option for patients with mild to moderate PMR, and when sarilumab (Kevzara), the only FDA-approved biologic for PMR, may be indicated in cases of moderate to severe disease, relapses, or steroid intolerance. Claudia

en

03:49

Medication Review: Leflunomide Medication Review

RhAPPcast ·

2025/08/14

In this educational session, Jessica Farrell, PharmD, from Albany Medical Center and Albany College of Pharmacy and Health Sciences, provides key clinical pearls on Leflunomide, a lesser-discussed DMARD (disease-modifying antirheumatic drug) used in rheumatology. While not frequently prescribed for new patients, many individuals remain on Leflunomide long-term, making it essential to understand its pharmacokinetics, potential toxicities, and considerations for special populations.A unique aspect of

en

38:14

RhAPPcast: Spotting the Signs: Recognizing and...

RhAPPcast ·

2025/08/12

In this debut episode of the GCA Fireside Chat series on RhAPPcast, host Amanda Mixon, PA-C, president of Rheumatology Advanced Practice Providers (RhAPP), sits down with expert guests Naomi Amudala, NP, and Rennie Rhee, MD, to explore one of the most critical aspects of giant cell arteritis (GCA) care—recognition. Together, they unpack how to differentiate routine headaches from those signaling GCA, discuss the nuanced role of labs, biopsies, and imaging in diagnosis, and share practical clinical

en

24:37

RhAPPcast: Foundations of PMR: Diagnosis, First-Line...

RhAPPcast ·

2025/08/05

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers (RhAPP), host Amanda Mixon, PA-C, is joined by seasoned rheumatology expert Heather Mambretti, PA-C, for a comprehensive discussion on polymyalgia rheumatica (PMR). Together, they explore foundational concepts and clinical challenges, including how to accurately diagnose PMR, differentiate it from mimickers like rheumatoid arthritis and paraneoplastic syndromes, and initiate appropriate glucocorticoid

en

06:51

Journal Club: Sarilumab for Relapse of Polymyalgia...

RhAPPcast ·

2025/07/22

In this journal club episode, Jeannette Hart, PA-C—co-founder of PNW Arthritis and Rheumatology and practicing at Kadlec Regional Medical Center in Washington—reviews pivotal findings from the SAPPHIRE trial, which led to the FDA approval of sarilumab for the treatment of polymyalgia rheumatica (PMR). Published in the New England Journal of Medicine in October 2023, this phase 3 randomized controlled trial evaluated the efficacy and safety of IL-6 receptor blockade with sarilumab in patients with

en

03:08

FAQ: Steroid-Sparing Agent Consideration in PMR...

RhAPPcast ·

2025/07/15

In this FAQ video, Claudia Rivera, NP, a rheumatology nurse practitioner from East Lansing, Michigan, discusses when to consider a steroid-sparing agent in the management of polymyalgia rheumatica (PMR) and what treatment options are available. While prednisone remains the cornerstone of PMR therapy, long-term steroid use poses significant risks including osteoporosis, diabetes, adrenal suppression, and infection. Claudia reviews guideline-based tapering strategies and highlights scenarios where

en

04:40

FAQ: What Are the Most Recent Treatment Guidelines...

RhAPPcast ·

2025/07/08

In this video, Kyle George, PA-C, a rheumatology physician assistant with St. Luke’s Rheumatology in Idaho, reviews the key clinical takeaways from the 2015 ACR and EULAR treatment guidelines for polymyalgia rheumatica (PMR). PMR is a common inflammatory condition in older adults, marked by bilateral shoulder or hip girdle pain and stiffness. Kyle discusses the diagnostic criteria, the hallmark rapid response to low-dose glucocorticoids, and the importance of screening for concurrent giant cell

en

01:23

Medication Review: What is the Mechanism of Action of...

RhAPPcast ·

2025/07/01

In this video, clinical pharmacist and RhAPP faculty member Danielle Gatti Palumbo breaks down the mechanism of action of methotrexate, explaining how this folate antimetabolite works to inhibit DNA synthesis, reduce inflammation, and regulate immune response. Methotrexate is a folate antimetabolite that plays a crucial role in inhibiting DNA synthesis, repair, and cellular replication, making it a widely used treatment for autoimmune diseases and certain cancers. Its primary mechanism involves

en

06:02

A Review of the Safety and Efficacy of...

RhAPPcast ·

2025/06/26

In this journal club session, Danielle Gatti-Palumbo, PharmD, a clinical pharmacist at Northwell Health Division of Rheumatology, explores the safety and efficacy of deucravacitinib, a first-in-class, oral selective TYK2 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis. Published in the Journal of Drugs in Dermatology (Feb 2025) by Dr. Milan Shaw and colleagues, the expert consensus review highlights six key recommendations based on a comprehensive literature review and

en

24:08

Understanding the TYK2/STAT Signaling Pathway in PsA:...

RhAPPcast ·

2025/06/19

In this episode of RhAPPcast, the official podcast of Rheumatology Advanced Practice Providers (RhAPP), host Amanda Mixon, PA-C, dives into the evolving role of TYK2 inhibition in the treatment of psoriatic arthritis (PsA). Joined by special guest and PsA expert Eileen Lydon, NP, the episode unpacks the science behind the TYK2/STAT signaling pathway, how it differs from traditional JAK inhibition, and what this means for patient care. Together, Amanda and Eileen explore key cytokines like IL-12,

en

03:36

Hydroxychloroquine Medication Review

RhAPPcast ·

2025/06/17

Hydroxychloroquine is a cornerstone therapy in rheumatology, offering significant benefits for mild rheumatoid arthritis (RA) and lupus. In this video, Jessica Farrell, PharmD, clinical pharmacist in rheumatology at Albany Medical Center and faculty at Albany College of Pharmacy and Health Sciences, explores the dosing, safety, and clinical applications of hydroxychloroquine.Jessica Farrell explains the weight-based dosing strategy (5 mg/kg/day) to minimize the risk of retinal toxicity, discusses

en

05:11

FAQ: How Does the Selectivity of TYK2 and JAK Enzyme...

RhAPPcast ·

2025/06/12

In this FAQ Video Module, Christy Vath, PA-C, a seasoned rheumatology expert from Seattle Rheumatology Associates, explores how the selectivity of TYK2 and JAK enzyme inhibition impacts safety profiles. She provides a clear comparison between traditional pan-JAK inhibitors and selective TYK2 inhibitors like deucravacitinib, highlighting their differing mechanisms of action and clinical implications.Christy breaks down how TYK2’s selective inhibition of the pseudokinase domain—versus the broader

en

121 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

Podcasts Archives - Extreme Health Radio

Justin Stellman

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Good Sleep: Positive Affirmations

Optimal Living Daily | Sleepy Meditation

Johannes Hansen Podcast

Johannes Hansen